Caplacizumab, Sanofi’s drug for a rare blood-clotting disorder, has been approved in Europe. U.S. approval is expected in early 2019 for the drug, which has been granted “fast-track” designation by the FDA. (Reuters)

Cancer researcher Yu Xue has pleaded guilty to conspiring to steal trade secrets from former employer GlaxoSmithKline. The judge has said that prosecutors don’t need to prove Xue understood the material, which she emailed to contacts in China, just that she understood it was confidential. (Endpoints News)

Patients are dying because they cannot afford insulin. The price of the hormone has more than doubled since 2012, leading to the dangerous practice of insulin rationing among uninsured patients and those with high deductibles. (NPR)

The FDA is set to hold a public hearing on Tuesday about how to increase competition in the biological products marketplace. The agenda includes a discussion about how to make biosimilar and interchangeable products more widely available. (FDA.gov)

After patients raised millions for funding a treatment for a rare disease, the drug was developed by a pharmaceutical company and assigned a high list price. Procysbi, a treatment for the rare childhood disease cystinosis, costs more than $1 million per year for some patients. (Daily Beast)